Spironolactone to Prevent Cardiovascular Events in Early Stage Chronic Kidney Disease (CKD): A Pilot Trial - STOP-CKD

niversity of Birmingham0 个研究点目标入组 240 人开始时间: 2012年5月11日最近更新: 2014年6月30日

适应症

试验速览

暂无简介。

•1. Age over 18 years
•2. Diagnosis of CKD Stage 3 (eGFR 30-59 ml/min/1.73m2) using the MDRD (Modification of Diet in Renal Disease) equation.
•Are the trial subjects under 18? no
•Number of subjects for this age range: 0
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 120
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 120

•Diabetes Mellitus
•Terminal disease or felt otherwise unsuitable by their general practitioner (GP)
•Chronic heart failure i.e. a clinical diagnosis or known ejection fraction (EF) <55%
•Atrial fibrillation
•Alcohol or drug abuse
•Inability to comply with trial medication and follow-up
•Documented previous hyperkalaemia or intolerance of spironolactone
•Documented Addison’s disease and/or on fludrocortisone
•Severe hypertension: blood pressure = 180/110 mmHg
•Systolic blood pressure less than 120mmHg
•Recent acute kidney injury or hospital admission (within past 6 weeks)
•Chronic diarrhoea
•ACR>70 mg/mmol (will require specialist referral if not already made)
•Serum potassium = 5 mmol/L on screening blood test
•Concomitant co-trimoxazole medication
•Concomitant angiotensin-converting enzyme inhibitor AND angiotensin II receptor blocker medication

发起方